The US FDA has approved a human papillomavirus (HPV) self-sampling solution developed by Roche that allows patients to collect a sample themselves in a healthcare setting.
Researchers have estimated that almost one in three men worldwide is infected with at least one genital human papillomavirus (HPV) strain, and one in five is harbouring st
Johnson & Johnson has halved the size of its collaboration with Bavarian Nordic on vaccine development, jettisoning its stake in shots targeting human papillomavirus (HPV) and hepatitis
Adding Nykode Therapeutics' VB10.16 vaccine to treatment with Roche's cancer immunotherapy Tecentriq resulted in disease control in two-thirds of patients with advanced cervical cancer.
Routine vaccination with human papillomavirus vaccines have resulted in an 87% reduction in cervical cancer cases in England, and could even see the need for smear tests phased out in futur